Life Sciences companies are attempting to improve compliance and manufacturing efficiency while they drive to grow revenue and margins. However, current market conditions are creating substantial headwinds to attaining these targets. Some of these headwinds originate with regulators, both because of increasingly complex global regulation and regulatory oversight, as well as recent FDA expectations that industry shift from a compliance view to an “organizational excellence” view.